CG Oncology, Inc. Common stock (CGON) financial statements
CG Oncology, Inc. Common stock reported revenue of $4M in fiscal 2025, up 345.0% a year over 2 years.
Net income was -$161M and the operating margin -4722.1%, against -27180.9% in 2023.
Free cash flow was -$132M.
The diluted share count rose 1685% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from CG Oncology, Inc. Common stock's 10-K filings with the SEC.
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $204,000 | $1M | $4M |
| Cost of revenue | — | — | $5M |
| Gross profit | — | — | -$607,000 |
| Research and development | $46M | $82M | $117M |
| Selling, general and admin | $10M | $34M | $74M |
| Operating income | -$55M | -$115M | -$191M |
| Income tax | $1,000 | $1,000 | -$270,000 |
| Net income | -$49M | -$88M | -$161M |
| EPS (diluted) | -$15.65 | -$1.41 | -$2.08 |
| Diluted shares | 4M | 62M | 77M |
| Gross margin | — | — | -15.0% |
| Operating margin | -27180.9% | -10067.3% | -4722.1% |
| Net margin | -23827.0% | -7729.5% | -3985.0% |
Balance sheet
Fiscal years, from CG Oncology, Inc. Common stock's 10-K filings with the SEC.
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Cash and short-term investments | $188M | $742M | $742M |
| Receivables | — | $0 | $688,000 |
| Inventory | — | $0 | $2M |
| Total current assets | $194M | $754M | $759M |
| Property, plant and equipment | $69,000 | $272,000 | $16M |
| Goodwill | — | $0 | $10M |
| Total assets | $199M | $755M | $792M |
| Total current liabilities | $14M | $21M | $31M |
| Long-term debt | — | $0 | $3M |
| Total liabilities | $15M | $21M | $39M |
| Shareholders' equity | -$123M | $733M | $753M |
| Net debt | -$8M | -$257M | -$29M |
Cash flow
Fiscal years, from CG Oncology, Inc. Common stock's 10-K filings with the SEC.
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating cash flow | -$46M | -$79M | -$132M |
| Capital spending | — | $234,000 | $134,000 |
| Free cash flow | — | -$79M | -$132M |
| Stock-based compensation | $2M | $11M | $27M |
| Free cash flow margin | — | -6931.3% | -3279.2% |
Questions
What was CG Oncology, Inc. Common stock's revenue in 2025?
$4M in fiscal 2025, from its 10-K filing.
How much free cash flow does CG Oncology, Inc. Common stock generate?
-$132M in fiscal 2025 (operating cash flow minus capital spending).
From CG Oncology, Inc. Common stock's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.